Investing News NetworkJune 25, 2024Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General and Special Meeting of Shareholders (the 'AGM') will be webcast on June 26, 2024, at 4:30 p.m.

投资新闻网2024年6月25日Cardiol Therapeutics Inc.（NASDAQ:CRDL）（TSX:CRDL）（“Cardiol”或“公司”）是一家临床阶段生命科学公司，专注于抗炎和抗纤维化治疗心脏病的研究和临床开发，宣布该公司的虚拟年度股东大会和特别股东大会（AGM）将于2024年6月26日下午4:30进行网络广播。

EDT.Cardiol Therapeutics 2024 AGMWhen: June 26, 2024, at 4:30 p.m. EDTWhere: Virtual meeting only via live audio webcast online at: web.lumiagm.com/253136217Additional information on the AGM, including details on how to participate and vote, is available on the Company's website at cardiolrx.com/investors/events-presentations/.

美国东部夏令时。Cardiol Therapeutics 2024年度股东大会时间：2024年6月26日下午4:30 EDT地点：虚拟会议仅通过在线直播音频网络广播：web.lumiagm.com/253136217有关年度股东大会的其他信息，包括如何参与和投票的详细信息，可在公司网站cardiolrx.com/investors/events-presentations/上获得。

About Cardiol TherapeuticsCardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.

关于Cardiol Therapeutics Inc.（纳斯达克：CRDL）（TSX:CRDL）是一家临床阶段生命科学公司，专注于用于治疗心脏病的抗炎和抗纤维化疗法的研究和临床开发。该公司的主要小分子候选药物CardiolRx™（大麻二酚）口服溶液是制药和临床开发中用于治疗心脏病的药物。

It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ('US FDA') to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent peri.

众所周知，大麻二酚抑制炎性体途径的激活，这是一种已知在与心肌炎，心包炎和心力衰竭相关的炎症和纤维化的发展和进展中起重要作用的细胞内过程。Cardiol已获得美国食品和药物管理局（US FDA）的研究性新药申请授权，进行临床研究，以评估CardiolRx™在两种影响心脏的疾病中的疗效和安全性：（i）II期多中心开放标签试验研究。